

Ambee Pharmaceuticals PLC
Audited Financial Statement
As on 30 June 2025

INDEPENDENT AUDITORS' REPORT
TO THE SHAREHOLDERS OF
AMBEE PHARMACEUTICALS PLC

Report on the Audit of the Financial Statements

Opinion

We have audited the financial statements of **AMBEE PHARMACEUTICALS PLC.** (the “Company”), which comprise the Statement of Financial Position as of 30th June 2025 and Statement of Profit or Loss and Other Comprehensive Income, Statement of Changes in Equity and Statement of Cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies.

In our opinion, except for the effects of the matters described in the *Basis for Qualified Opinion* section of our report, the accompanying financial statements of the Company give a true and fair view of the financial position of the Company as at 30th June 2025, and of its financial performance and its cash flows for the year then ended in accordance with International Financial Reporting Standards (IFRSs), the Companies Act 1994, the Securities and Exchange Rules 1987 and other applicable laws and regulations.

Basis for Qualified Opinion

- a) As disclosed in note # 20.00, Tk. 1,916,358 is shown as Payable to Provident Fund, carried forward from prior years. Although the fund is a recognized fund (Note 3.07 (a)), no contributions have been made during the year under audit.
- b) As disclosed in Note 6.00, the company has an investment of Tk. 52,604,603 in Bengal Meat Processing Industries Ltd, including 4,610,000 acquired between 12th January 2017 to 30th June 2024 but those were not previously recorded & disclosed in the financial statements. Moreover, during the year under audit, the company has paid Tk. 6,504,603 against issuance of 650,460 no. right shares which are yet to be issued. No paper regarding the investment in shares including right shares could be shown to us except a photocopy of certificate issued by Bengal Meat Processing Industries Ltd. During the current year, the company recognized these shares by debiting Investment in Shares and crediting Liabilities for Other Finance - Ambee Ltd. This delayed recognition is a departure from IFRS requirements relating to the timely recognition and measurement of financial assets. Furthermore, no dividend income has been recognized to date, based on a declaration from the investee, which creates uncertainty regarding the recoverability and valuation of this investment. No satisfactory explanation could be given to us for non-disclosure of the above investment in previous years.

Emphasis of Matter

We refer note no.20.00 which needs attention of the management details of the same have been disclosed in note 20.01.

We conducted our audit in accordance with International Standards on Auditing (ISAs). Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountants' Code of Ethics for Professional Accountants (IESBA Code) together with the ethical requirements that are relevant to our audit of the financial statements in Bangladesh, and we have fulfilled our other ethical responsibilities in accordance with these ethical requirements and the IESBA Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our qualified opinion and Disclaimer of opinion.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Valuation of Property, Plant and Equipment (PPE)	
See Note 4.00 to the financial statements	
The key audit matter	How the matter was addressed in our audit
<p>The carrying value of the PPE was Tk. 102,560,566 as of 30 June 2025.</p> <p>Expenditures are capitalized if they create new assets or enhance the existing assets, and expensed if they relate to repair or maintenance of the assets. Classification of the expenditures involves judgment. The useful lives of PPE items are based on management’s estimates regarding the period during which the assets or its significant components will be used. The estimates are based on historical experience and market practice and take into consideration the physical condition of the assets.</p> <p>The valuation of PPE was identified as a key audit matter due to the significance of this balance to the financial statements and that there is significant measurement uncertainty involved in this valuation.</p>	<p>Our audit included the following procedures: We assessed whether the accounting policies in relation to the capitalization of expenditures follow IFRS and found them to be consistent.</p> <p>We obtained a listing of capital expenditures incurred during the year and on a sample basis, checked whether the items were procured based on internal purchase order that had been properly approved by the responsible individuals.</p> <p>We inspected a sample of invoices and L/C documents to determine whether the classification between capital and revenue expenditure was appropriate.</p> <p>We evaluated whether the useful lives determined and applied by the management were in line with historical experience and the market practice.</p> <p>We checked whether the depreciation of PPE items was commenced timely, by comparing the date of the reclassification from capital work in progress to ready for use, with the date of the act of completion of the work.</p>

Implementation of IFRS 16 Leases	
See Note 5.00 to the financial statements	
The key audit matter	How the matter was addressed in our audit
<p>The Right of use (ROU) of Tk. 823,195 as of 30th June 2025 IFRS 16 modifies the accounting treatment of operating leases at inception, with the recognition of a right of use (ROU) on the leased assets and of a liability for the lease payments over the lease contract term. With respect to operating leases of premises used by the Company, at inception of the lease, the lessee receives a right of using the premises, in exchange of a lease debt, using an implicit discount rate.</p> <p>All leasing arrangements within the scope of IFRS 16 are identified and appropriately included in the calculation of the transitional impact and specific assumptions applied to determine the discount rates for lease are appropriate.</p>	<p>We reviewed appropriateness of management’s application of IFRS 16 and assessment of the impact on the financial statements. Our audit procedures included testing classification and measurement of right-of-use assets and lease liabilities in accordance with IFRS 16. We checked the present value calculation for lease.</p> <p>We reviewed loan agreements and made calculation to ascertain the appropriateness of the incremental borrowing rate used. We also examined the accuracy and appropriateness of accounting adjustments in the financial statements arising from the adoption of IFRS 16 as well as verified the sufficiency and appropriateness of disclosures in the financial statements.</p>

Valuation of Inventory	
See Note 6.00 to the financial statements	
The key audit matter	How the matter was addressed in our audit
<p>The inventory of Tk. 210,799,122 as of 30th June 2025 held in factory, depots and outlets.</p> <p>Inventories are carried at the lower of cost and net realizable value.</p> <p>Since the value of Inventory is significant to the Financial Statements and there is significant measurement uncertainty involved in this valuation, the valuation of inventory was significant to our audit.</p>	<p>We verified the appropriateness of management's assumptions applied in calculating the value of the inventory by:</p> <ul style="list-style-type: none"> • Evaluating the design and implementation of key inventory controls operating across the factory. • Attending inventory counts and reconciling the counts results to the inventory listings to test the completeness of data. • Evaluating, on a sample basis, whether inventories were stated at the lower of cost or net realizable value at the reporting date by comparing the sales prices of inventories after the reporting date; and • Evaluating the adequacy of financial statement disclosure as per IAS – 2.
Cash & Cash Equivalents	
See Note 12.00 to the financial statements	
The key audit matter	How the matter was addressed in our audit
<p>Cash & Cash Equivalents Tk. 32,641,615 as of 30th June 2025 represents Cash in Hand and Cash with banks at the close of business of the company which can be used without any obligation.</p> <p>As those are liquid funds, as per practice it is important to confirm and verify the actual balances of cash & cash equivalent.</p>	<ul style="list-style-type: none"> • We could not physically verify the cash in hand at branches except that of Head Office. However, the cash balance is duly certified by the management. • We send 7 letters to cover 14 bank accounts to confirm their balances as on 30th June 2025 directly to us, but we have received confirmations accordingly.
Deferred Tax Liability	
See Note 16.00 to the financial statements	
The key audit matter	How the matter was addressed in our audit
<p>The Deferred Tax Liability balance was Tk. 3,849,700 as of 30th June 2025.</p> <p>Significant management judgment is required in relation to deferred tax Liability as it is dependent on forecasts of future profitability over several years.</p> <p>There is significant measurement uncertainty involved in this valuation and therefore it was significant to our audit.</p>	<p>We carried out the following substantive testing to address the related risk:</p> <ul style="list-style-type: none"> • We obtained an understanding, evaluated the design and tested the operational effectiveness of the Company's key controls over the recognition and measurement of deferred tax Liability assumptions used in estimating the Company's future taxable income. • We also assessed the completeness and accuracy of the data used for the estimations of future taxable income. • We assessed key assumptions, controls, recognition and measurement of Deferred Tax Liability. <p>We also assessed the appropriateness of presentation of disclosure against IAS-12 Income Taxes.</p>

Workers Profit Participation Fund:	
See Note 22.00 to the financial statements	
The key audit matter	How the matter was addressed in our audit
<p>As per section 234(1)(b) of Bangladesh Labor Act 2006 (as amended in 2013) 5% of the annual net profit must be allocated to workers profit participation and welfare funds within nine months from the end of the financial year. Of this amount, 80% is to be transferred to the Worker's participation fund and 10% to the worker's welfare fund. The remaining 10% must be paid to the worker's welfare Foundation fund under the Bangladesh Workers' welfare foundation act 2006. Further, two-thirds of the workers' participation fund is to be distributed in cash to eligible employees and one-third invested in accordance with Section 242 of the Act.</p> <p>Due to the regulatory requirements and judgement involved in calculating and distributing the funds, this area was considered significant for our audit.</p>	<p>We reviewed the provision, distribution, and compliance requirements relating to WPPF and WWF and identified certain instances of non-compliance with the Labour Act 2006 (as amended in 2013)</p> <p>During the year, Tk. 10,496,466 was distributed to eligible employees. However, an undistributed balance remains outstanding, and interest on this amount has been recognized in the accounts.</p> <p>Distribution, of WPPF fund has been made without following the required rules of WPPF Fund.</p>
Revenue Recognition	
See Note 24.00 to the financial statements	
The key audit matter	How the matter was addressed in our audit
<p>At year end the company reported total revenue of BDT 230,551,023 (2024: BDT 219,303,514) Revenue recognition has a significant and wide influence on the financial statements. Revenue is recognized when the amounts and the related costs are reliably measured, and the performance obligation is complete through passing of control to the customers. Revenue from the sale of goods is recognized at the time when the goods are dispatched for delivery to the customer.</p> <p>We identified revenue recognition as a key audit matter because revenue is one of the key performance indicators of the Company and therefore there is an inherent risk of manipulation of the timing of recognition of revenue by management to meet specific targets or expectations.</p>	<p>Our audit procedures in this area included, among others:</p> <ul style="list-style-type: none"> • We understood, evaluated and validated the key controls related to the Company's sales process from end to end, from contracts approval and sign-off, recording of sales, all the way through to cash receipts and customers' outstanding balances. • Furthermore, we tested the sales transactions recognized shortly before and after the statement of financial position date, including the sales returns recorded after that date, to test whether sales transactions were recorded in the correct reporting periods. • Finally, we assessed the appropriateness and presentation of disclosures against IFRS 15 Revenue from Contracts with Customers.
Transactions with Related Parties	
See Note 33.00 to the financial statements	
The key audit matter	How the matter was addressed in our audit
<p>We considered the related party transactions to be significant to the audit due to the risk that if these transactions are not conducted at arm's length, and/or the accounting treatment of the rights and obligations of these transactions are not correct, it could influence the results of the financial statement. Furthermore, for financial reporting purposes, IAS 24 related party disclosure, requires complete and appropriate disclosure of transactions with related parties.</p>	<p>Our audit procedures included, among others, the following:</p> <ul style="list-style-type: none"> • We obtained an understanding of the process for identifying related party transactions. • We verified that the transactions are approved in accordance with internal procedures including involvement of key personnel at the appropriate level.

Transactions with Related Parties	
See Note 33.00 to the financial statements	
The key audit matter	How the matter was addressed in our audit
	<ul style="list-style-type: none"> • We checked the acquisitions to supporting documents including external valuations around the acquisition date to evaluate the managements’ assertions that the transactions were at arm’s length. • We evaluated the business rationale of the transactions. • We evaluated the rights and obligations per the terms and conditions of the agreements and assessed whether the transactions were recorded appropriately; and <p>We determined whether the directors have disclosed relationships and transactions in accordance with IAS 24.</p>
Contingent Liabilities	
See Note 38.00 to the financial statements	
The key audit matter	How the matter was addressed in our audit
<p>The Company is subject to several significant claims and litigations. The amounts of claims are significant and estimates of the amounts of provisions or contingent liabilities are subject to significant management judgment. These claims and regulatory matters are uncertain in timing of resolutions and amount or consequences.</p> <p>These claims and litigation matters were a key audit matter due to the amounts involved, potential consequences and the inherent difficulty in assessing the outcome. The assessment of whether or not a liability should be recognized involves judgment from management.</p>	<p>We obtained an understanding, evaluated the design and tested the operational effectiveness of the Company’s key controls over the legal provision and contingencies process.</p> <p>We enquired to those charged with governance to obtain their view on the status of the litigation.</p> <p>We enquired of the Company’s internal legal counsel for the litigation and inspected internal notes and reports.</p> <p>We assessed the methodologies on which the provision amounts are based, recalculated the provisions, and tested the completeness and accuracy of the underlying information.</p> <p>We also assessed the Company’s provisions and contingent liabilities disclosure.</p>
Contingent Liabilities	
The key audit matter	How the matter was addressed in our audit
<p>Our audit procedures have a focus on information technology systems and controls due to the pervasive nature and complexity of the IT environment, the large volume of transactions processed in numerous locations daily and the reliance on automated and IT dependent manual controls.</p> <p>Our areas of audit focus included user access management, developer access to the production environment and changes to the IT environment. These are key to ensuring IT dependent and application-based controls are operating effectively.</p>	<p>We tested the design and operating effectiveness of the Company’s IT access controls over the information systems that are critical to financial reporting. We tested IT general controls (Logical access, changes management and aspects of IT operational controls). This included testing that requests for access to systems were appropriately reviewed and authorized.</p> <p>We tested the Company’s periodic review of access rights. We inspected requests of changes to systems for appropriate approval and authorization. We considered the control environment relating to various interfaces, configuration and other application layer controls identified as key to our audit.</p>

Independent Auditor's Report (continued)

Shafiq Basak & Co.
Chartered Accountants

Other Information

Balance Confirmation of Accounts Receivable & Sundry Creditors:

- a) A detailed list and contact information for the respective parties were not provide to us. Consequently, we were unable to circulate balance confirmation requests for direct verification of balances as of 30 June 2025.
- b) Due to the above limitation, we are unable to obtain sufficient appropriate audit evidence regarding the accuracy and completeness of the se balances and therefore cannot express an opinion on their correctness.

Management is responsible for the other information included in the Annual Report, excluding the financial statements and our auditors' report thereon. The Annual Report is expected to be made available to us after the date of this auditor's report.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information identified above when it becomes available and, in doing so, consider whether the other information is materially inconsistent with the financial statements, or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on such work we perform, we conclude that there is a material misstatement of this other information, we are required to communicate the matter to those charged with governance.

Responsibilities of Management and Those Charged with Governance for the Financial Statements and Internal Controls

Management is responsible for the preparation and fair presentation of the financial statements of the Company in accordance with IFRSs, The Companies Act 1994, The Securities and Exchange Rules 1987 and other applicable laws and regulations and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with International Standards on Auditing (ISAs) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with International Standards on Auditing (ISAs), we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the internal controls of the Company.

Independent Auditor's Report (continued)

Shafiq Basak & Co.
Chartered Accountants

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.


From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditors' report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on other Legal and Regulatory Requirements

In accordance with the Companies Act 1994, The Securities and Exchange Rules 1987 and relevant notifications issued by Bangladesh Securities and Exchange Commission, we also report that:

- a) We have obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit and made due verification thereof.
- b) In our opinion, proper books of accounts as required by law have been kept by the Company in computerized excel sheet so far as it appeared from our examination of those records.
- c) The Company's Statement of Financial Position and Statement of Profit or Loss and Other Comprehensive Income dealt with by this report are in agreement with the books of accounts and.
- d) The expenditures incurred and payment made were for the purpose of the Company's business for the year.


Place: Dhaka
Dated: 09 November 2025


(Sarwar Mahmood FCA)
Partner
Shafiq Basak & Co.
Chartered Accountants
DVC: 2511090239AS143965

AMBEE PHARMACEUTICALS PLC
Statement of Financial Position
As at 30th June 2025

Particulars	Notes	Amount in Taka	
		30 June 2025	30 June 2024
<u>ASSETS</u>			
Non-Current Assets		155,988,364	85,101,743
Property, Plant & Equipment	4.00	102,560,566	83,833,723
Right-of-Use Asset (ROU)	5.00	823,195	1,268,020
Investment in Shares	6.00	52,604,603	-
Current Assets:		577,568,806	504,843,148
Inventories	7.00	210,799,122	221,913,784
Short Term Investment (FDR)	8.00	100,000,000	-
Accounts Receivable	9.00	194,837,808	180,645,492
Advance Income Tax	10.00	21,146,980	21,296,958
Advances, Deposits and Pre-payments	11.00	18,143,281	48,245,246
Cash & Cash Equivalents	12.00	32,641,615	32,741,668
Total Assets		733,557,170	589,944,891
<u>EQUITY & LIABILITIES</u>			
Shareholders' Equity		32,334,070	29,424,676
Share Capital	13.00	24,000,000	24,000,000
Tax-Holiday Reserve	14.00	5,134,154	5,134,154
Retained Earnings	15.00	3,199,916	290,522
Non-Current Liabilities		4,051,248	4,757,595
Deferred Tax Liability	16.00	3,849,700	4,513,016
Lease Finance (Non-Current Portion)	17.01	201,548	244,579
Current Liabilities and Provision		697,171,852	555,762,620
Lease Finance (Current Portion)	17.01	237,242	596,456
Creditors for Goods & Others	18.00	6,125,490	5,587,452
Liabilities for Expenses	19.00	7,543,004	7,111,693
Liabilities for Other Finance	20.00	661,122,119	499,182,072
Provision for Income Tax	21.00	18,406,533	25,163,893
Workers Participation and Welfare Fund	22.00	3,310,067	13,120,582
Advance Received Against Export Sales	-	-	4,624,955
Unclaimed Dividend	23.00	427,397	375,518
Total Equity and Liabilities		733,557,170	589,944,891
Net Asset Value (NAV) Per Share	29.00	13.47	12.26


The accounting policies and other notes 1.00 to 40.00 & Schedule-A to B form an integral part of the Financial Statements. The Financial statements were authorized for issue by the Board of Directors on 30-10-2025 and signed on its behalf by:




Kazi Tanzzina Ferdous
Managing Director & CEO




Sakina Miraly
Director



Nurjehan Hudda
Director




A.K.M. Khairul Aziz
Chief Financial Officer



Mohammad Amir Hossain
Company Secretary

Signed in terms of our separate report of even date annexed


Place: Dhaka
Date: 09 November 2025


(Sarwar Mahmood FCA)
Partner
Shafiq Basak & Co.
Chartered Accountants
DVC: 2511090239AS143965

AMBEE PHARMACEUTICALS PLC
Statement of Profit or Loss and Other Comprehensive Income
For the year ended 30th June 2025

Particulars	Notes	Amount in Taka	
		30 June 2025	30 June 2024
Revenue (Net)	24.00	230,551,023	219,303,514
Cost of Goods Sold	25.00	(121,119,693)	(105,130,747)
Gross Profit		109,431,330	114,172,767
Operating Expenses		(101,357,216)	(99,790,596)
Administrative Expenses	26.00	(17,636,581)	(17,758,371)
Selling, Distribution & Marketing Expenses	27.00	(83,720,635)	(82,032,226)
Profit from Operations		8,074,114	14,382,169
Financial Expenses	28.00	(390,568)	(1,926,848)
Profit before contribution to WPWF		7,683,546	12,455,322
Contribution to WPWF	22.00	(384,177)	(622,766)
Profit before Tax		7,299,369	11,832,557
Income Tax Expenses		(1,989,975)	(2,149,070)
Income Tax Expenses- Current Year	21.00	(2,653,291)	(3,759,478)
Deferred Tax (Expenses)/ Income	16.00	663,316	1,610,408
Net Profit after Tax		5,309,394	9,683,487
Earnings Per Share (EPS) Basic	30.00	2.21	4.03

The accounting policies and other notes 1.00 to 40.00 & Schedule-A to B form an integral part of the Financial Statements. The Financial statements were authorized for issue by the Board of Directors on 30-10-2025 and signed on its behalf by:



Kazi Tanzzina Ferdous
Managing Director & CEO



Sakina Miraly
Director



Nurjehan Hudda
Director



A.K.M. Khairul Aziz
Chief Financial Officer



Mohammad Amir Hossain
Company Secretary

Signed in terms of our separate report of even date annexed

Place: Dhaka
Date: 09 November 2025


(Sarwar Mahmood FCA)
Partner
Shafiq Basak & Co.
Chartered Accountants
DVC: 2511090239AS143965

AMBEE PHARMACEUTICALS PLC

Statement of Changes in Equity


For the year ended 30th June, 2025

Particulars	Amount in Taka			
	Share Capital	Tax Holiday Reserve	Retained Earnings	Total
Balance as on 01 July 2024	24,000,000	5,134,154	290,522	29,424,676
Cash Dividend for the year 2023-2024	-	-	(2,400,000)	(2,400,000)
Net Profit during the year after Tax	-	-	5,309,394	5,309,394
Balance as on 30 June 2025	24,000,000	5,134,154	3,199,916	32,334,070

For the year ended 30th June, 2024

Particulars	Amount in Taka			
	Share Capital	Tax Holiday Reserve	Retained Earnings	Total
Balance as on 01 July 2023	24,000,000	5,134,154	(5,792,964)	23,341,190
Cash Dividend for the year 2022-2023	-	-	(3,600,000)	(3,600,000)
Net Profit for the year after Tax	-	-	9,683,487	9,683,487
Balance as on 30 June 2024	24,000,000	5,134,154	290,522	29,424,676

The accounting policies and other notes 1.00 to 40.00 & Schedule-A to B form an integral part of the Financial Statements. The Financial statements were authorized for issue by the Board of Directors on 30-10-2025 and signed on its behalf by:




Kazi Tanzina Ferdous
Managing Director & CEO




Sakina Miraly
Director



Nurjehan Hudda
Director




A.K.M. Khairul Aziz
Chief Financial Officer



Mohammad Amir Hossain
Company Secretary

Signed in terms of our separate report of even date annexed

Place: Dhaka
Date: 09 November 2025


(Sarwar Mahmood FCA)
Partner
Shafiq Basak & Co.
Chartered Accountants
DVC: 2511090239AS143965


AMBEE PHARMACEUTICALS PLC

Statement of Cash Flows

For the year ended 30th June, 2025

Particulars	Notes	Amount in Taka	
		30 June 2025	30 June 2024
A) Cash Flows from Operating Activities:			
Cash Receipts from Customers & Others	7.00	216,358,707	174,601,977
Payments for Costs, Expenses & Others		(188,732,373)	(224,108,062)
Cash Generated from Operating Activities		27,626,334	(49,506,085)
Finance Expenses		(390,568)	(1,926,848)
Income Tax Paid		(5,501,195)	(14,490,261)
Net Cash Generated from Operating Activities	32.00	21,734,571	(65,923,194)
B) Cash Flows from Investing Activities:			
Purchase of Property, Plant & Equipment		(23,794,746)	(2,201,280)
Short Term Investment (FDR)		(100,000,000)	-
Investment in Share		(52,604,603)	-
Net Cash (Used in)/Generated from Investing Activities		(176,339,349)	(2,201,280)
C) Cash Flows from Financing Activities:			
Other Finance		161,940,047	81,819,882
Short Term Borrowings		-	(11,480,430)
Advance Received against Export Sales		(4,624,955)	4,624,955
Lease Finance		(402,245)	714,636
Dividend Paid		(2,348,121)	(3,380,834)
Net Cash Used in Financing Activities		154,564,727	72,298,209
D) Net Change in Cash and Cash Equivalents (A+B+C)		(100,053)	4,173,735
E) Opening Cash and Cash Equivalents		32,741,668	28,567,933
F) Closing Cash and Cash Equivalents (D+E)	10.00	32,641,615	32,741,668
Net Operating Cash Flow Per Share (NOCFPS)	31.00	9.06	(27.47)


The accounting policies and other notes 1.00 to 40.00 & Schedule-A to B form an integral part of the Financial Statements. The Financial statements were authorized for issue by the Board of Directors on 30-10-2025 and signed on its behalf by:




Kazi Tanzina Ferdous
Managing Director & CEO




Sakina Miraly
Director



Nurjehan Hudda
Director




A.K.M. Khairul Aziz
Chief Financial Officer



Mohammad Amir Hossain
Company Secretary

Signed in terms of our separate report of even date annexed

Place: Dhaka
Date: 09 November 2025


(Sarwar Mahmood FCA)
Partner
Shafiq Basak & Co.
Chartered Accountants
DVC: 2511090239AS143965

AMBEE PHARMACEUTICALS PLC
Notes to the Financial Statements
For the year ended 30th June, 2025

1.00 Background and Introduction:

1.01 Incorporation and Legal Status

The Ambee Pharmaceuticals PLC. was incorporated in Bangladesh as a public company on 4th February, 1976 vide Certificate of Incorporation No. C-4714/132 of 1975-1976. It commenced commercial operation in 1978 and went for public issue of shares in 1986. The shares of the Company are listed in the Dhaka and Chittagong Stock Exchanges of Bangladesh.

The registered office and the manufacturing plant of the company is located at 184/1, Tejgaon I/A, Dhaka-1208, Bangladesh.

1.02 Nature of Business

The nature of business of the company is to manufacture, buy, sell, export, or otherwise deal in all kinds of drugs, medicines, Pharmaceuticals, chemicals, medical or any other preparations and to refine, manipulate or treat all such substances used in pharmaceutical industry and to do all such acts necessary in connection with any business or chemists, druggists, chemical and medicine manufacturers, pharmacists etc.

2.00 Basis of Preparation of Financial Statements:

2.01 Basis of Measurement:

The financial statements have been prepared on the Historical Cost Convention. The financial statements therefore, do not take into consideration the effect of inflation.

2.02 Statement of Compliance:

The Financial statements have been prepared in compliance with disclosures and presentational requirement of:

- Bangladesh Securities and Exchange Rules, 2020
- The Income Tax Act, 2023 with subsequent amendments;
- The Value Added Tax Act, 2012 with subsequent amendments
- The Value Added Tax Rules, 2012 with subsequent amendments;
- The Labor Act, 2006 with subsequent amendments in 2013
- The Labor Law Rules 2015; and
- Others as applicable

2.03 Compliance with International Financial Reporting Standards:

IAS	Title	Remarks
IAS 1	Presentation of Financial Statements	Complied
IAS 2	Inventory	Complied
IAS 7	Statement of Cash Flows	Complied
IAS 8	Accounting Policies, Changes in Accounting Estimates and Errors	Complied
IAS 10	Events after the Reporting Period	Complied
IAS 12	Income Taxes	Complied
IAS 16	Property, Plant and Equipment	Complied
IAS 17	Leases	Complied
IAS 19	Employee Benefits	Complied
IAS 20	Accounting for Government Grants and Disclosure of Government Assistance	N/A
IAS 21	The Effects of Changes in Foreign Exchange Rates	N/A
IAS 23	Borrowing Costs	Complied
IAS 24	Related Party Disclosures	Complied
IAS 26	Accounting and Reporting by Retirement Benefit Plans	N/A
IAS 27	Separate Financial Statements	N/A
IAS 28	Investments in Associates and Joint Ventures	N/A
IAS 31	Interests in Joint Ventures	N/A
IAS 32	Financial Instruments: Presentation	Complied
IAS 33	Earnings per Share	Complied
IAS 34	Interim Financial Reporting	Complied
IAS 36	Impairment of Assets	Complied
IAS 37	Provisions, Contingent Liabilities and Contingent Assets	Complied

IAS	Title	Remarks
IAS 38	Intangible Assets	Complied
IAS 39	Financial Instruments: Recognition and Measurement	Complied
IAS 40	Investment Property	N/A
IAS 41	Agriculture	N/A
IFRS 1	First Time Adoption	N/A
IFRS 2	Share Based Payment	N/A
IFRS 3	Business Combinations	N/A
IFRS 4	Insurance Contracts	N/A
IFRS 5	Non-Current Assets Held for Sale and Discontinued Operations	N/A
IFRS 6	Exploration for and Evaluation of Mineral Resources	N/A
IFRS 7	Financial Instruments: Disclosures	Complied
IFRS 8	Operating Segments	N/A
IFRS 10	Consolidated Financial Statements	N/A
IFRS 11	Joint Arrangements	N/A
IFRS 12	Disclosure of Interest in Other Entities	Complied
IFRS 13	Fair Value Measurement	Complied
IFRS 14	Regulatory Deferral Accounts	N/A
IFRS 15	Revenue from contracts with customers	Complied
IFRS 16	Leases	Complied

2.03 Reporting Period

The financial statements cover the period of 12 months from July 01, 2024 to June 30, 2025.

2.04 Functional and Presentation Currency

The financial statements are prepared and presented in Bangladesh Currency (Taka), which is the Company's functional currency. Figures have been rounded off to the nearest Taka except where indicated otherwise.

2.05 Comparative Information:

Comparative information has been disclosed for all numerical information in the financial statements and also the narrative and descriptive information where it is relevant for understanding of the current period's financial statements.

Comparative information has been rearranged, wherever considered necessary, to ensure better presentation and comparability with the current year.

2.06 Use of Estimates and Judgements:

The preparation of financial statements in conformity with International Financial Reporting Standards (IFRSs) including International Accounting Standards (IASs) require management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses, and for contingent assets and liabilities that require disclosure, during and at the date of the financial statements.

Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Any revision of accounting estimates is recognized in the period in which the estimate is revised and in any future periods affected.

In particular, the key areas of estimation, uncertainty and critical judgments in applying accounting policies that have the most significant effect on the amounts recognized in the financial statements include depreciation, inventory valuation, current and deferred taxes, accrued expenses and other payables.

3.00 Significant Accounting Policies

The Company has consistently applied the following accounting policies to all periods presented in these financial statements.

3.01 Property, Plant and Equipment

3.1.1 Recognition and Measurement

Items of Property, Plant and Equipment excluding land are measured at cost less accumulated depreciation in compliance with the requirements of IAS 16: "Property, Plant and Equipment".

The cost of acquisition of an asset comprises of its purchase price and directly attributable cost of bringing the asset to its working condition for its intended use inclusive of inward freight, duties and non-refundable taxes.

3.1.2 Maintenance Activities

The Company incurs maintenance costs for all its major items of Property, Plant and Equipment. Repair and maintenance costs are charged as expenses when incurred. In the situation where it can be clearly demonstrated that the expenditure has resulted in an increase in the future economic benefit expected to be obtained from the use of the fixed assets, the expenditure is capitalized as an additional cost of the assets.

3.1.3 **Depreciation**

- a) Land is held on freehold basis and is not depreciated considering the infinite life.
- b) In respect of all other PPE, depreciation is charged using Reducing Balance Method.
- c) Full month depreciation is charged on assets from when the assets are available for use, while no depreciation is charged in the month of disposal.
- d) The Company reviews the non-current assets' useful life every year and there is no change in the estimated useful life.

The depreciation rate for the current and the previous years are as follows:

Particulars	Rate of Depreciation	
	30 June 2025	30 June 2024
Factory Building	10%	10%
Plant & Machinery	20%	20%
Deep Tube Well	10%	10%
Diesel Generating Set	15%	15%
Loose Tools	10%	10%
Laboratory Equipment	10%	10%
Electrical Installation	10%	10%
Laboratory Glassware	10%	10%
Production Equipment	10%	10%
Transport and Vehicles	20%	20%
Motor Cycle	20%	20%
Furniture and Fixtures	10%	10%
Office Equipment	10%	10%
Office By-Cycles	20%	20%
Books	10%	10%

3.1.4 **Retirements and Disposals:**

On disposal of PPE, the cost and accumulated depreciation are eliminated and gain or loss on such disposal is reflected in the Statement of Profit or Loss and Other Comprehensive Income, which is determined with reference to the net book value of the assets and net sale proceeds or realized amount.

3.1.5 **Impairment**

The Company assesses at each reporting date whether there is any indication that an asset may be impaired. If any such indication exists, the Company estimates the recoverable amount of the asset and impairment loss is recognized in the statement of profit or loss and other comprehensive income. There is no impairment loss during the year under review.

3.1.6 **Capital Work-in-Progress:**

The non-current assets which are not ready for use at the year end, are shown as capital work-in-progress and subsequently those assets would have to be transferred to property, plant and equipment when all the necessary works are completed.

3.02 **Right of Use Asset (ROU):**

All leasing arrangements except those having less than 12 months of useful life and underlying asset values of less than Taka 425,000 when new, have been capitalized as "right-of-use" asset with a corresponding financial liability on the financial position.

Leased assets are capitalized from the start date of the lease agreement at the present value of the future lease payments, based on the rate of interest entered in the asset master data. Low value (<Taka 425,000) and short-term leases (<12months) have been excluded from the recognition requirements and charged to statement of profit or loss as rental costs. Lease reassessment and lease modification to increase/decrease the value of an asset depending on a change in scope of lease agreement can be made if necessary.

The asset is written off on a straight-line basis over the tenure of the lease agreements. Hence, the useful life of any lease assets depends on the periods the assets can be used. The useful life of such assets are dependent on individual agreement and can vary from one agreement to another.

3.03 **Borrowing Cost:**

Borrowing costs are recognized as expenses in the period in which they are incurred unless capitalization of such is allowed under IAS 23: "Borrowing Costs".

3.04 Accounts Receivable and Others:

Accounts receivable are initially recognized at invoice amounts which is the fair value of the consideration given in return.

Provisions for doubtful debts are made where there is evidence of a risk of non-payment, taking into account aging, previous experience as well as general economic conditions and ultimately the prospects of realizability.

3.05 Inventories:

Inventories are carried at the lower of cost and net realizable value as prescribed by IAS 2: "Inventories". Cost is determined on a weighted average cost basis. Net realizable value of the finished goods is determined at selling price in the ordinary course of business less costs to sell, while raw and packing materials as well as accessories and components are valued at cost including expenses incurred for acquiring the inventories.

3.06 Provisions:

A provision is recognized in the financial statements when the Company has a legal or constructive obligation as a result of a past event, it is probable that an outflow of economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. Provision is ordinarily measured at the best estimate of the amount to be required to settle the present obligation at the date of statement of financial position.

3.07 Employee Benefits:

The Company operates a defined contributory provident fund and Workers' Participation and Welfare Fund for its eligible permanent employees. The eligibility is determined according to the terms and conditions set forth in respective deeds. The details of employee benefits are as under:

a) Provident Fund (Defined Contribution Plan):

The Company has a recognized provident fund scheme (Defined Contribution Plan) for employees of the Company eligible to be members of the fund in accordance with the rules of the provident fund constituted under an irrevocable Trust. All permanent employees contribute a certain percentage of their basic salary to the provident fund and the Company also makes equal contribution.

The Company recognizes contribution to defined contribution plan as an expense when an employee has rendered services against such contribution. The legal and constructive obligation is limited to the amount it agrees to contribute to the fund.

b) Contribution to Workers' Participation and Welfare Fund:

This represents 5% of net profit before tax contributed by the Company as per provisions of the Labour Act, 2006 with subsequent amendments and is transferred to Ambee Pharmaceuticals Limited Workers' Participation and Welfare Fund. The trustee of the fund manages the distribution of the WPWF according to the guidelines of the Labour Act, 2006 with subsequent amendments

3.08 Revenue Recognition:

The Company recognizes as revenue the amount that reflects the consideration to which the Company expects to be entitled to receive in exchange for goods or services when (or as) it transfers control to the customer. To achieve that core principle, this standard (IFRS 15) establishes a five-step model as follows:

- Identify the contract with a customer;
- Identify the performance obligations in the contract;
- Determine the transaction price;
- Allocate the transaction price to the performance obligations in the contract; and
- Recognize revenue when (or as) the entity satisfies a performance obligation.

Considering the five steps model, the Company recognizes revenue when (or as) the Company satisfies a performance obligation by transferring a promised goods to a customer. Goods are considered as transfer when (or as) the customer obtains control of that goods. Revenue from sale of goods is measured at the fair value of the consideration received or receivable net off returns and allowances, trade discounts, rebates and Value Added Tax (VAT).

3.09 Leases:

The Company assesses at contract inception whether a contract is, or contains, a lease. That is, if the contract conveys the right to control the use of an identified asset for a period in exchange for consideration.

Company as a Lessee

The Company applies a single recognition and measurement approach for all leases, except for short-term leases and leases of low-value assets. The Company recognizes lease liabilities to make lease payments and right-of-use assets representing the right to use the underlying assets.

i) Right of Use Assets (ROU)

The Company recognizes right-of-use assets at the commencement date of the lease (i.e., the date the underlying asset is available for use). Right-of-use assets are measured at cost, less any accumulated depreciation and impairment losses, and adjusted for any measurement of lease liabilities. The cost of right-of-use assets includes the amount of lease liabilities recognized and lease payments made at or before the commencement date.

ii) Lease Liabilities

At the commencement date of the lease, the Company recognizes lease liabilities measured at the present value of lease payments to be made over the lease term. In calculating the present value of lease payments, the Company uses its incremental borrowing rate at the lease commencement date because the interest rate implicit in the lease is not readily determinable. After the commencement date, the amount of lease liabilities is increased to reflect the accretion of interest and reduced for the lease payments made. In addition, the carrying amount of lease liabilities is remeasured if there is a modification, a change in the lease term, a change in the lease payments or a change in the assessment of an option to purchase the underlying asset.

iii) Short-Term Leases and Leases of Low-Value Assets

The Company does not apply the recognition and measurement requirements of IFRS 16 to short-term leases (leases of less than 12 months maximum duration). It also does not apply the recognition and measurement requirements of IFRS 16 to leases for which the underlying assets are low value (i.e., less than Taka 425,000 when new). Lease payments on short-term leases and leases of low-value assets are recognized as expense on a straight-line basis over the lease term.

3.10 Income Tax Expense:

(a) Current Tax

Income tax expense for current year is recognized on the basis of Company's computation based on the best estimated assessable profit for the year at the applicable tax rate pursuant to provisions of Income Tax Act, 2023. The tax rates for the period are applied based on the enacted tax rates in the relevant Finance Acts.

(b) Deferred Tax

Deferred tax is provided on temporary differences arising between the tax base of assets and liabilities and their carrying amounts in the financial statements in accordance with the provisions of IAS 12: "Income Taxes". Current ruling tax rate is used in the determination of deferred tax.

(c) Provision for Income Tax & Assessment Position:

The assessment of the company has been completed up to the assessment year 2023-2024 (Accounting year 30-06-2023). Except assessment years 2005-2006, 2010-2011, 2011-2012, 2012-2013 and 2014-2015. The provision for Income tax and Advance Income Tax for these assessment years has been shown in note 18.00 and note 07.00 separately.

3.11 Earnings Per Share (EPS):

This has been calculated in compliance with the requirements of IAS 33: "Earnings per share". Earnings per share equals the basic earnings divided by the weighted average number of ordinary shares outstanding during the period.

3.12 Foreign Currency Transactions:

Foreign currency transactions are recorded at the applicable rates of exchange ruling at the transaction date.

The monetary assets and liabilities, denominated in foreign currencies at the financial position date are translated at the applicable rates of exchange ruling at that date. Exchange differences are treated as revenue/expense in compliance with the provisions of IAS 21: "The Effects of Changes in Foreign Exchange Rates".

3.13 Statement of Cash Flows:

The statement of cash flows has been prepared in accordance with the requirements of IAS 7: "Statement of Cash Flows". The cash generated from operating activities has been reported using the direct method as prescribed by the Securities and Exchange Rules, 2020 and following the benchmark treatment of IAS 7, whereby major classes of gross cash receipts and gross cash payments from operating activities are disclosed.

In accordance with the gazette notification dated 08 August 2018 from Bangladesh Securities and Exchange Commission, an additional disclosure on reconciliation of net cash flows from operating activities making adjustments for non-cash items, non-operating and net changes in operating accruals has been provided in note 32.00.

Notes Sl. No.	Particulars	Note Ref. No.	Amount in Taka	
			30 June 2025	30 June 2024
4.00	Property Plant & Equipment:			
	(A) Cost		255,965,473	232,170,727
	Opening Balance		232,170,727	229,969,447
	Addition during the year		23,794,746	2,201,280
	Adjustment during the year		-	-
	(B) Accumulated Depreciation		153,404,907	148,337,004
	Opening Balance		148,337,004	142,493,912
	Addition during the year		5,067,903	5,843,092
	Adjustment during the year		-	-
	Written Down Value(A-B)		102,560,566	83,833,723
	Details of Property Plant & Equipment are shown in Schedule-A			
5.00	Right of Use Asset (ROU), Net:			
	Opening Balance		1,268,020	137,342
	Addition during the year		-	1,334,475
			1,268,020	1,471,817
	Depreciation charged during the year	26.00	(444,825)	(203,797)
	Closing Balance		823,195	1,268,020
6.00	Investment in Share			
	Bengal Meat Processing Industries Ltd		52,604,603	-
			52,604,603	-
	During the year, the Company acquired 5,260,460 ordinary shares of Bengal Meat Processing Industries Ltd. at a total cost of Tk. 52,604,603. Ownership of the shares has been duly transferred to the Company. The investment has been recognized at cost, in accordance with the requirements of IFRS 9 – Financial Instruments, as the shares are unquoted equity instruments for which no active market exists to determine a reliable fair value. Accordingly, the investment is carried at cost less impairment, if any, as at the reporting date.			
7.00	Inventories			
	Raw materials		52,913,643	34,287,452
	Packing materials		31,723,240	31,025,478
	Promotional materials		548,710	425,874
	Work-in-process		7,703,550	18,754,257
	Finished goods		117,909,979	133,534,859
	Materials-in-transit		-	3,885,864
	Closing Balance		210,799,122	21,913,784
8.00	Short Term Investment (FDR):			
	Mutual Trust Bank Ltd, A/c. No: 1306011168567		50,000,000	-
	Dutch Bangla Bank PLC., A/c. No.		50,000,000	-
			100,000,000	-
9.00	Accounts Receivables:			
	Opening Balance		180,645,492	135,943,955
	Addition during the year	24.00	230,551,023	219,303,514
			411,196,515	355,247,469
	Received during the year		(216,358,707)	(174,601,977)
	Closing Balance		194,837,808	180,645,492
	Details of Accounts Receivable are given below:			
	Above Six Months		98,098,349	96,587,452
	Below Six Months		96,739,459	84,058,040
			194,837,808	180,645,492

Accounts receivable is considered good in terms of security and previous collection history. Party wise balance of receivables are not available.

Notes Sl. No.	Particulars	Note Ref. No.	Amount in Taka	
			30 June 2025	30 June 2024
10.00	<u>Advance Income Tax:</u>			
	Opening Balance		21,296,958	19,578,293
	Addition during the year		3,609,500	4,354,463
			24,906,458	23,932,756
			(3,759,478)	(2,635,798)
			21,146,980	21,296,958
11.00	<u>Advances, Deposits and Prepayments</u>			
	i) Advances		18,097,566	45,949,457
	Advances to Staff (Salary & Travelling)		3,884,521	3,658,741
	Advance Rent		180,000	180,000
	Against Purchases and Expenses		13,935,059	31,238,640
	Bengal Steel Works Limited		-	10,774,090
	Ambee Films Limited		97,986	97,986
	ii) Deposits		20,715	2,270,789
	L/C Margin		-	2,250,074
	Guarantee Margin		20,715	20,715
	iii) Prepayments		25,000	25,000
	WASA		25,000	25,000
	Total (i to iii)		18,143,281	48,245,246
12.00	<u>Cash and Cash Equivalents:</u>			
	Cash in Hand	12.01	30,003,633	31,169,675
	Cash at Bank	12.02	57,415	57,415
	In-Operative Accounts	12.03	2,580,567	1,514,578
			32,641,615	32,741,668
12.01	<u>Cash in Hand:</u>			
	Head Office		17,806	40,272
	Factory		11,892	42,957
	DASC		33,679	109,156
	DBSC		2,458,741	2,363,123
	MNSC		3,158,720	3,165,777
	BGSC		3,069,852	3,282,221
	RJSC		3,144,571	3,090,180
	RNSC		3,025,604	3,268,671
	BLSC		3,060,210	3,267,815
	KLSC		2,987,524	3,178,354
	CMSC		3,222,050	3,181,027
	CGSC		2,767,963	3,043,657
	SLSC		3,045,021	3,136,465
			30,003,633	31,169,675
	The above balances are certified by a cash custody certificate.			
12.02	<u>In-Operative Accounts:</u>			
	Agrani Bank Ltd. Press Br. Club Acc-892-4		321	321
	Agrani Bank Ltd. Chatterwari Road Br. Acc-1840		397	397
	Agrani Bank Ltd. Cumilla Br. CA Acc-52982		99	99
	Habib Bank Ltd. Dhaka. Acc-5133-72		6	6
	Sonali Bank Custom House Br. CD-A-3		25,327	25,327
	Arab Bangladesh bank Ltd. Acc-1962		29,349	29,349
	First Security Bank Ltd. Dhaka. Acc-1100724-9		100	100
	Agrani Bank, Battala Br. Barisal. Acc-33002491		816	816
	Agrani Bank Ltd. Central Road br. Rangpur. C/A Acc-4752		1,000	1,000
			57,415	57,415

Notes Sl. No.	Particulars	Note Ref. No.	Amount in Taka	
			30 June 2025	30 June 2024
12.03	Cash at Bank			
	Eastern Bank Ltd., Gulshan Branch Dhaka, A/C # 104-107-0000-139		28,842	29,532
	Eastern Bank Ltd., Gulshan Branch Dhaka, A/C # 104-107-0004854		3,059	3,749
	Sonali Bank Ltd., Gulshan Branch Dhaka, A/C # 33004754		211,431	212,237
	Sonali Bank Ltd., Gulshan New North Circle Branch, A/C # 011633002105		13,070	4,582
	Agrani Bank Ltd, Amin Court Branch, CD A/C # 0004263		56,075	56,880
	Agrani Bank Ltd, Amin Court Branch, Dividend A/C # 0001724		1,258,819	700,710
	United Commercial Bank Ltd., CD A/C # 0951101000002665 (Dormant)		233,779	234,619
	United Commercial Bank Ltd., Tejgaon Branch, CD A/C # 1041101000000972		704,415	206,235
	Dutch-Bangla Bank Ltd., A/c. No. 2271100018251		2,592	2,710
	Dutch-Bangla Bank Ltd., A/c. No. 2271100018272		2,715	2,575
	Dutch-Bangla Bank Ltd., A/c. No. 2271100018267		2,803	2,218
	Dutch-Bangla Bank Ltd., A/c. No. 2271100020748		2,770	-
	Dutch-Bangla Bank Ltd., A/c. No. 2271100106537		2,701	-
	Padma Bank Ltd., A/c. No. 0060111000147		57,496	58,531
			2,580,567	1,514,578

Above balances have been confirmed with the respective bank statements & certificates.

13.00	Share Capital			
	a) Authorized			
	30,000,000 Ordinary Shares of Taka 10 each		300,000,000	300,000,000
	b) By Cash Issued Subscribed and Paid-Up Capital			
	i) 1,821,008 Ordinary Shares of Tk. 10 each fully Paid Up in cash.		18,210,080	18,210,080
	ii) Other than Cash			
	178,992 Ordinary Shares of Tk. 10 each paid-up in full for consideration other than cash		1,789,920	1,789,920
	c) By issue of Bonus Share			
	400,000 Bonus Shares of Tk.10 each Issued for the year 2013		4,000,000	4,000,000
			24,000,000	24,000,000

13.01 Composition of Shareholdings

Particulars	30 June 2025		30 June 2024	
	No. of Shares	%	No. of Shares	%
Sponsors, Directors & Associates	1,639,269	68.30	1,639,269	68.30
ICB & Institutions	207,792	8.66	130,372	5.43
Foreign Investors	214,790	8.95	214,790	8.95
General Public	338,149	14.09	415,569	17.32
	2,400,000	100.00	2,400,000	100.00

13.02 The distribution schedule showing the number of shareholders' and their shareholdings in Percentage has been disclosed as a requirement of the "Listing Regulation" of Dhaka and Chittagong Stock Exchanges as on 30th June, 2025.

Range of Holdings	No. of Shareholders	No. of Shares	Holdings (%)
01 to 500 shares	1,696	113,201	4.72
501 to 5,000 shares	77	100,030	4.17
5,001 to 10,000 shares	7	50,733	2.11
10,001 to 20,000 shares	2	22,400	0.93
40,001 to 50,000 shares	4	192,120	8.01
50,001 to 100,000 shares	3	259,577	10.82
100,001 to 1,000,000 shares	1	214,790	8.95
Over 1,000,000 shares	1	1,447,149	60.30
	1,791	2,400,000	100.00

13.03 The share is listed in the Dhaka and Chittagong Stock Exchange On 30.06.2025 each share was quoted at Tk 816.50/- in the Dhaka Stock Exchange Ltd. and Tk 800.00 the Chittagong Stock Exchange Ltd.

14.00 Tax Holiday Reserve:	5,134,154	5,134,154
This was created out of profit during Tax-Holiday period to invest in the same undertaking or in any new industrial undertaking or in stocks and shares of a public company or in government bonds or securities or for other purposes as specified in this respect as one of the conditions of granting Tax Holiday. But no such investment has been made.		

Notes Sl. No.	Particulars	Note Ref. No.	Amount in Taka	
			30 June 2025	30 June 2024
15.00	<u>Retained Earnings</u>			
	Opening Balance		290,523	(5,792,964)
	Addition during the year		5,309,394	9,683,487
			5,599,917	3,890,523
	Dividend Paid during the year (2023-2024)		(2,400,000)	(3,600,000)
			3,199,917	290,523
16.00	<u>Deferred Tax Liabilities:</u>			
	Carrying value of depreciable PPE-As per Accounts	Schedule-A	52,311,025	33,584,182
	Tax Base Value	Schedule-B	(35,585,652)	(13,953,316)
			16,725,373	19,630,866
	Temporary difference for IFRS 16: Lease		384,405	426,985
	Tax Base Value		-	-
			384,405	426,985
	Net taxable temporary difference- Liabilities		17,109,779	20,057,851
	Tax Rate		22.50%	22.50%
	Deferred Tax Liability- Closing		3,849,700	4,513,016
	Deferred Tax Liability- Opening		4,513,016	6,123,425
	Deferred Tax (Expenses)/Income for the year		663,316	1,610,408
16.01	The temporary difference figure has been computed by deducting ROU Assets from Lease liabilities and multiply by 22.5% tax rate thereon in order to calculate deferred tax (assets)/liability value.			
17.00	<u>Lease Finance:</u>			
	Loan From Lease Finance		-	-
	Current Portion of long-term loan being payable within one year		-	-
			-	-
17.01	<u>Leases:</u>			
	Opening Balance as at 1st July, 2024		841,035	126,399
	Addition during the year		-	1,154,475
	Interest Accrued during the year		88,795	140,223
			929,830	1,421,097
	Payments during the year		(491,040)	(580,062)
	Closing Balance		438,790	841,035
	Lease Liabilities Recognized in Statement of Financial Position			
	Lease Liability - Net off Current Maturity		201,548	244,579
	Lease Liability - Current Maturity		237,242	596,456
			438,790	841,035
18.00	<u>Creditors for Goods & Others:</u>			
	This represents amounts due to various suppliers of raw, packing and stores materials, the ageing of which liability is as follows:			
	Above six months		-	-
	Below six months		6,125,490	5,587,452
			6,125,490	5,587,452
19.00	<u>Liabilities for Expenses:</u>			
	This represents provision for various expenses (e.g., remuneration and allowances, salaries and wages, utilities bill etc.), which have fallen due as on 30th June, 2025, ageing of which liability is as follows			
	Above six months		-	-
	Below six months		7,543,004	7,111,693
			7,543,004	7,111,693
	<u>Details of above balance are given below:</u>			

Notes Sl. No.	Particulars	Note Ref. No.	Amount in Taka	
			30 June 2025	30 June 2024
	Salary, wages & Allowance		4,728,426	5,450,381
	Electricity, Gas & Water		725,487	681,615
	Audit Fees		402,500	402,500
	Telephone & Internet Bill		87,541	74,601
	TA/DA/Other		549,403	502,596
	TDS Payable		1,049,647	-
			7,543,004	7,111,693
20.00	<u>Liabilities for other Finance:</u>			
	Employees Income Tax		701,137	701,137
	Provident Fund Payable		1,916,358	1,916,358
	Mr. Aziz Mohammad Bhai		193,093,891	190,093,891
	Mrs. Kazi Tanzina Ferdous		-	1,000,000
	Ambee Limited		308,148,651	282,469,031
	Bengal Steel Works Ltd		137,260,427	-
	Others Payable	20.01	20,001,655	20,001,655
			661,122,119	499,182,072
20.01	Out of the total balance of Tk. 661,122,119, an amount of Tk. 193,093,891 is payable to Aziz Mohammad Bhai, Chairman of the Company, as disclosed in Note # 33.00 'Related Party Transactions.' Additionally, an amount of Tk. 20,001,665 as interest payable under 'Others Payable' has been carried forward from previous years which may not be payable. Amount payable to Ambee Limited represents temporary interest free loan which is supported by a certificate from Ambee Limited.			
21.00	<u>Provision for Income Tax:</u>			
	Opening Balance		25,163,893	31,540,212
	Provision for the year	21.01	2,653,291	3,759,478
	Adjustment during the year		27,817,184	35,299,690
	Closing Balance		18,406,533	25,163,893
21.01	<u>Current Year's Tax Provision</u>			
	Profit before tax for the Year		7,299,369	11,832,556
	Business Income			
	Provision for Inadmissible Items and Possible Add-backs		1,587,542	1,458,586
	Accounting Depreciation		5,067,903	5,843,092
	Tax Base Depreciation		(2,162,410)	(2,425,442)
	Taxable Income		11,792,404	16,708,792
	Total Tax Expense		-	-
	Tax on Business Income 22.5%		2,653,291	3,759,478
	Year wise Tax Provision are given below			
	<u>Assessment years</u>	<u>Accounting Year</u>		
	2004-2005	30-06-2004	-	1,651,173
	2005-2006	30-06-2005	4,722,496	8,722,496
	2010-2011	30-06-2010	2,302,815	2,302,815
	2011-2012	30-06-2011	2,637,588	2,637,588
	2012-2013	30-06-2012	2,228,549	2,228,549
	2014-2015	30-06-2014	3,861,794	3,861,794
	2024-2025	30-06-2024	-	3,759,478
	2025-2026	30-06-2025	2,653,291	-
			18,406,533	25,163,893

Notes Sl. No.	Particulars	Note Ref. No.	Amount in Taka	
			30 June 2025	30 June 2024
22.00	<u>Workers Profit Participation Fund (WPPF)</u>			
	Opening Balance		13,120,582	11,713,039
	Provision during the year		384,177	622,766
	Interest during the year @ 11.5%	28.00	301,773	1,347,000
			13,806,533	13,682,805
	Paid during the year		(10,496,466)	(562,223)
	Closing Balance		3,310,067	13,120,582
23.00	<u>Unclaimed Dividend</u>			
	The following figures represent the dividends for which the warrants are either lying with the shareholders and have not been presented as yet by them to the bank for encashment or have been returned to the company undelivered due to change of address of those shareholders and their new address have not yet been communicated to the company. Under instruction from SEC, press advertisements were made to collect the past dividend warrants but many shareholders are yet turn up to collect their respective warrants.			
	Opening Balance		375,518	1,356,352
	Add: Dividend during the year		2,400,000	3,600,000
			2,775,518	4,956,352
	Less: Dividend paid during the year	2,063,334		
	Dividend Tax paid during the year	284,787	2,348,121	3,580,834
	Less: Transfer to Capital Market Stabilization Fund (CMSF)		-	1,000,000
			427,397	375,518
24.00	<u>Revenue</u>			
	Local Sales		253,169,262	252,199,041
	Value Added Tax (VAT)		33,022,078	32,895,527
			220,147,184	219,303,514
	Export Sales during the year		10,403,839	-
			230,551,023	219,303,514
24.01	<u>Sales Quantity:</u>			
		UOM	Qty	
	Tablet	Pcs	48,886,949	110,546,054
	Capsules	Pcs	36,216,702	104,534,920
	Liquids	Bottles	345,968	5,833,598
	Ointment	Pcs	4,078	39,720
	Injection	Ampoule	1,019,588	9,596,731
			86,473,285	230,551,023
				219,303,514
25.00	<u>Cost of Goods Sold:</u>			
	Work-in-process (Opening)		18,754,257	15,875,426
	Raw materials consumed	25.01	33,346,129	57,651,809
	Packing materials consumed	25.02	27,878,533	33,007,194
	Promotional materials consumed	25.03	812,808	1,080,294
	Factory overhead	25.04	30,443,003	29,370,254
	Depreciation	Schedule - A	3,218,507	3,799,182
	Work-in-process (Closing)		(7,703,550)	(18,754,257)
	Cost of production		106,749,687	122,029,901
	Stock of finished goods (Opening)		133,534,859	117,661,579
	Stock of finished goods (Closing)		(117,909,979)	133,534,859
	Cost of free samples		(1,254,874)	(1,025,874)
			121,119,693	105,130,747
25.01	<u>Raw Materials Consumption</u>			
	Opening Stock		34,287,452	24,058,754
	Purchase		51,972,320	67,880,507
	Closing Stock		(52,913,643)	(34,287,452)
			33,346,129	57,651,809

Raw materials consumption is 79.11% imported.

Notes Sl. No.	Particulars	Note Ref. No.	Amount in Taka	
			30 June 2025	30 June 2024
25.02	<u>Packing Materials Consumed</u>			
	Opening Stock		31,025,478	28,763,547
	Purchase		28,576,295	35,269,125
	Closing Stock		(31,723,240)	(31,025,478)
			<u>27,878,533</u>	<u>33,007,194</u>
	Packing materials consumed is 0% imported.			
	Particulars in respect of quantity of each packing materials as well as value of each class of packing materials are not given as number of items as well as classes of items are large.			
25.03	<u>Promotional Materials Consumed:</u>			
	Opening Stock		425,874	445,874
	Purchase		935,644	1,060,294
	Closing Stock		(548,710)	(425,874)
			<u>812,808</u>	<u>1,080,294</u>
	Particulars in respect of quantity of each promotional materials as well as value of each class of promotional materials are not given as number of items as well as classes of items are large.			
25.04	<u>Factory Overhead:</u>			
	Salary, wages and allowances		24,603,184	22,641,384
	Overtime allowances		146,001	591,897
	Car Expenses		137,184	582,134
	Electricity, Gas and Water		4,691,591	4,387,111
	Conveyance		43,369	56,811
	Entertainment		17,931	51,798
	Printing and Stationery		101,700	137,795
	Repairs and maintenance		177,073	385,692
	Telephone & Mobile		86,321	142,012
	Indirect materials-Packing		172,985	194,150
	Uniform		-	6,699
	License Renewal		186,876	-
	General Expenses		-	76,414
	Washing & Laundry Expenses		15,113	49,957
	Power & Fuel		63,675	66,400
			<u>30,443,003</u>	<u>29,370,254</u>
26.00	<u>Administrative Expenses</u>			
	Salary and Allowances		11,111,595	11,855,678
	Car Expenses		252,586	290,909
	Bank Charges		126,397	72,672
	Conveyance		110,361	176,375
	Entertainment		117,522	211,649
	Printing and Stationery		116,618	152,891
	Electricity, Gas and Water		1,172,895	1,096,779
	Repairs and Maintenance		25,899	98,840
	Telephone & Mobile		570,602	505,172
	Fees and Commissions		109,445	120,547
	Membership Subscription		330,609	328,950
	Govt. Fees		151,730	-
	Audit Fees (Statutory)		402,500	402,500
	Insurance Premium		620,053	45,872
	Legal and Professional Charges		18,000	22,410
	AGM Expenses		98,460	93,550
	Advertisement & Publicity		7,088	35,871
	Depreciation		1,849,396	2,043,910
	Depreciation on Right of Use Asset	Schedule-A 5.00	444,825	203,797
			<u>17,636,581</u>	<u>17,758,372</u>

Notes Sl. No.	Particulars	Note Ref. No.	Amount in Taka	
			30 June 2025	30 June 2024
27.00	<u>Selling, Distribution and Marketing Expenses</u>			
	Salary and Allowances		63,759,112	65,033,327
	Overtime Allowance		149,080	-
	Rent, Rates and Taxes		432,000	687,542
	Incentive		672,764	687,556
	Car Expenses		-	87,542
	Bank charges		316,856	306,864
	Commercial Booking Cost		424,106	792,625
	Conveyance		213,300	252,487
	Entertainment		14,910	24,955
	Printing and Stationery		196,514	113,734
	Repairs and maintenance		84,525	18,091
	Telephone		324,768	82,795
	Electricity, Gas and Water		277,514	262,487
	Commission Charge		-	110,547
	TA/DA of MR and others		5,622,915	5,590,889
	License & Renewals		72,352	-
	Power & Fuel		35,929	-
	Clinical Fees		471,500	-
	Meeting/Conference/Training expenses		76,380	45,872
	Indirect materials-Packing		640,490	-
	Delivery Van expenses		110,167	80,554
	Delivery expenses		7,337,470	6,948,872
	Free Sample		2,487,983	905,487
			83,720,635	82,032,226
28.00	<u>Financial Expenses</u>			
	Interest on Overdraft/LTR		-	579,848
	Interest on Lease Finance		88,795	-
	Interest on WPWF	22.00	301,773	1,347,000
			390,568	1,926,848
29.00	<u>Net Assets Value (NAV) Per Share:</u>			
	Non-Current Assets		155,988,364	85,101,743
	Current Assets		577,568,806	504,843,148
	Non-Current Liabilities		4,051,248	4,757,595
	Current Liabilities		697,171,852	555,762,620
			32,334,070	29,424,676
	Total number of ordinary shares		2,400,000	2,400,000
			13.47	12.26
30.00	<u>Earnings Per Share (EPS)</u>			
	Earning attributable to the Ordinary Shareholders (Net Profit/Loss after tax)		5,309,394	9,683,487
	Weighted average number of Ordinary shares outstanding during the year		2,400,000	2,400,000
			2.21	4.03
31.00	<u>Net Operating Cash Flow Per Share (NOCFPS)</u>			
	Cash flows from net operating activities as per statement of cash flows		21,734,571	(65,923,194)
	Weighted average number of ordinary shares outstanding during the year		2,400,000	2,400,000
			9.06	(27.47)

Notes Sl. No.	Particulars	Note Ref. No.	Amount in Taka	
			30 June 2025	30 June 2024
32.00	<u>Cash Flow from Operating Activities (Indirect Method):</u>			
	Reconciliation of Net Profit with Cash Flows from Operating Activities making adjustment for non-cash items, for non-operating items and for the Net changes in Operating Activities (as required under the provision of Notification No. BSEC/CMRRCD/2006-158/208/Admin/81 dated 20 June 2018 issued by Bangladesh Securities and Exchange Commission)			
	Net Profit after Tax		5,309,394	9,683,487
	Adjustments		5,512,728	6,046,889
	Depreciation on Property, Plant & Equipment		5,067,903	5,843,092
	Depreciation on Right of Use Asset		444,825	203,797
	Changes in Working Capital		10,912,449	(81,653,568)
	Increase in Inventories		11,114,662	(24,665,859)
	Increase in Accounts Receivable & Others		(14,192,316)	(45,625,603)
	Increase in Advances, Deposits & Prepayments		30,101,965	(4,755,931)
	Increase in Advances Income Tax		149,978	(1,718,665)
	Decrease in Creditor for Goods		538,038	605,469
	Decrease in Liabilities for Expenses		431,311	1,086,206
	Increase in Provision for Income Tax		(7,420,676)	(7,986,728)
	Increase in Worker Profit Participation Fund		(9,810,515)	1,407,543
	Net Cash Generated from Operating Activities		21,734,571	(65,923,194)

33.00 Related Party Transactions- Disclosure Under IAS 24:

The Company has entered into transactions with other entities that fall within the definition of related party as contained in IAS-24 "Related Party Disclosures". The Company opines those terms of related party transactions do not significantly differ from those that could have been obtained from third parties. Total transactions of the significant related parties as at 30 June 2025 were as follows:

Name of the Party	Relations hip	Nature of Transaction	Notes	Opening Balance	Addition during the year	Adjustment during the year	Closing Balance
Bengal Steel Works Limited	Group Concern	Inter Company Loan/ Receivables	9.00	(10,774,090)	148,034,517	-	137,260,427
Ambee Films Limited	Group Concern	Inter Company Loan/ Receivables	9.00	97,986	-	-	97,986
Kazi Tazzina Ferdous	Managing Director	Inter Company Loan/ Receivables	18.00	1,000,000	-	1,000,000	-
Ambee Limited	Group Concern	Inter Company Loan/ Receivables	18.00	282,469,031	45,679,620	20,000,000	308,148,651
Aziz Mohammad Bhai	Chairman	Inter Company Loan/ Receivables	18.00	193,093,891	-	-	193,093,891
Total:				465,886,818	193,714,137	21,000,000	638,600,955

Note: Out of total amount of Tk. 308,148,651 of Ambee Limited from the above table, The amount of Tk. 45,679,620 is included from the running year 2025. Company will take permission from the shareholders in the next Annual General Meeting.

34.00 Salaries / Perquisites to Directors & Officers:

During the year, the amount of compensation paid to Key Management Personnel including Board of Directors is as under (As Para 17 of IAS 24 Related Party Disclosures):

Short Term Employee Benefits	99,473,891	96,616,374
Post- Employment Benefits	-	-
Other Long-Term Benefits	-	-
Termination Benefits	-	-
Bonus	2,877,452	2,914,015
Total	102,351,343	99,530,389

There is no other benefits provided by the company to its employees other than a contribution Provident Fund Scheme.

Notes Sl. No.	Particulars	Note Ref. No.	Amount in Taka	
			30 June 2025	30 June 2024

34.01 Directors Remuneration:
During the year total remuneration paid to directors amounting to Tk. Nil.

34.02 Number of Employees:
Total number of employees of the Company was 474 as on 30 June, 2025.
Total number of employees of the Company was 529 as on 30 June, 2024.

35.00 Financial Risk Management:

(a) Credit risk

Credit risk is the risk of a financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations and arises principally from the Company's receivables. Management has a credit policy in place and exposure to credit risk is monitored on an ongoing basis. Risk exposures from other financial assets, i.e., cash at bank and other external receivables are nominal.

Exposure to Credit Risk

Accounts Receivable & Others	9.00	194,837,808	180,645,492
Cash & Cash Equivalents	12.00	32,641,615	32,741,668
		227,479,423	213,387,160

The aging of Trade Receivables at the reporting date was:

Dues below 6 months	96,739,459	84,058,040
Dues over 6 months	98,098,349	96,587,452
	194,837,808	180,645,492

b) Liquidity Risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations when they fall due. The Company's approach to managing liquidity (cash and cash equivalents) is to ensure, as far as possible, that it will always have sufficient liquidity to meet its liabilities when due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to the Company's reputation. Typically, the Company ensures that it has sufficient cash and cash equivalents to meet expected operational expenses, including financial obligations through preparation of the cash flow forecast, prepared based on time line of payment of the financial obligation and accordingly arrange for sufficient liquidity/fund to make the expected payment within due date. In extreme stressed conditions, the Company may get support from the related Company in the form of short-term financing.

(c) Market risk

Market risk is the risk that any change in market prices such as foreign exchange rates and interest will affect the Company's income or the value of its holdings of financial instruments. The objective of market risk management is to manage and control market risk exposures within acceptable parameters.

(i) Currency risk

The Company is exposed to currency risk on certain purchases such as import of raw & packing materials, machineries and equipment. Majority of the Company's foreign currency transactions are denominated in USD and relate to procurement of raw & packing materials, machineries and equipment from abroad.

(ii) Interest rate risk

Interest rate risk is the risk that arises due to changes in interest rates on borrowing. There was no foreign currency loan which is subject to floating rates of interest. Local loans are, however, not significantly affected by fluctuations in interest rates. The Company has not entered into any type of derivative instrument in order to hedge interest rate risk as at the reporting date.

36.00 Production Capacity & Capacity Utilization:

Products	On single shift basis		Remarks
	Production Capacity	Actual Production	
Tablet group (Pcs)	1,250,000	1,180,000	As per market demand
Capsule group (Pcs)	500,000	45,000	As per market demand
Suspension group (Bottles)	10,000	8,500	-do-
Injectable (Ampoules)	35,000	32,000	-do-
Tube	8,500	7,000	-do-

37.00 Capital Expenditure Commitment:

The Board of Directors of the company adopted the following decisions with regard to Capital Expenditures:
There was no material capital expenditure authorized by the Board but not contracted for at 30 June 2025.

Notes Sl. No.	Particulars	Note Ref. No.	Amount in Taka	
			30 June 2024	30 June 2023

38.00 Contingent Liabilities

There may arise contingent liability for unassessed income tax cases pending with Tax Department.

39.00 Payments made in Foreign Currency:

Import of Raw material	40,634,473	51,753,067
Import of Packing material	-	-
	<u>40,634,473</u>	<u>51,753,067</u>

No other expenses including royalty, technical expert and professional advisory fees, interest etc. was incurred or paid in foreign currencies except as stated above.

40.00 Going Concern:

The financial statements of the Company are prepared on a going concern basis. As per management assessment there are no material uncertainties related to events or conditions which may cast significant doubt upon Company's ability to continue as a going concern. The management is not aware of any other material uncertainties that may cast significant doubt upon the Company's ability to continue as a going concern, which is most unlikely though yet considering overall perspectives.

41.00 Subsequent Events-Disclosures under IAS 10 "Events after the Balance Sheet Date"


Proposed Dividend

Subsequent to the statement of financial position date, the Board of Directors in their meeting held on 30-10-2025 recommended 10% cash dividend (i.e., taka 1.00 for each share of taka 10.00) for the year ended 30th June 2025. The proposal is subject to the shareholders' approval at the forthcoming AGM.

Excepting to that, no circumstances have arisen since the date of statement of financial position which would require adjustment to, or disclosure in, the financial statements or notes thereto.

42.00 Approval of the Financial Statements:

These financial statements were authorized for issue in accordance with the resolution of the Company's Board of Directors in its meeting held on 30-10-2025.



Kazi Tanzzina Ferdous
Managing Director & CEO



A.K.M. Khairul Aziz
Chief Financial Officer

Signed in terms of our separate report of even date annexed

Place: Dhaka
Date: 09 November 2025




Sakina Miraly
Director



Nurjehan Hudda
Director



Mohammad Amir Hossain
Company Secretary


(Sarwar Mahmood FCA)
Partner
Shafiq Basak & Co.
Chartered Accountants
DVC: 2511090239AS143965

AMBEE PHARMACEUTICALS PLC.
Schedule of Property, Plant & Equipment
For the year ended 30th June 2025

Schedule-A

Particulars	Cost			Depreciation			Written Down Value as on 30.06.2025		
	Balance as on 01.07.2024	Addition during the Year	Adjustment the during year	Balance as on 30.06.2025	Rate %	Balance as on 01.07.2024		Adjustment during the year	Charged during the Year
Existing Units -1									
Land	49,033,738	-	-	49,033,738	-	-	-	-	49,033,738
Leasehold Land	1,215,803	-	-	1,215,803	-	-	-	-	1,215,803
Factory Building	26,326,964	-	-	26,326,964	10	16,992,797	933,417	17,926,213	8,400,751
Plant and Machinery	62,248,702	23,590,846	-	85,839,548	20	54,064,086	1,636,923	55,701,009	30,138,539
Deep Tube Well	1,368,000	-	-	1,368,000	10	1,235,714	13,229	1,248,942	119,058
Diesel Generating Set	446,500	-	-	446,500	15	402,979	6,528	409,507	36,992
Loose Tools	98,001	-	-	98,001	10	96,100	190	96,290	1,711
Laboratory Equipment	3,977,036	-	-	3,977,036	10	2,757,088	134,771	2,891,859	1,085,177
Electrical Installation	556,455	-	-	556,455	10	361,504	19,495	380,999	175,455
Laboratory Glassware	41,626	-	-	41,626	10	41,557	7	41,564	62
Production Equipment	1,220,541	-	-	1,220,541	10	974,911	24,563	999,474	221,067
Transport and Vehicles	12,530,135	-	-	12,530,135	20	11,428,517	220,324	11,648,840	881,295
Motor Cycle	38,662,774	-	-	38,662,774	20	32,827,561	1,167,043	33,994,604	4,668,170
Furniture and Fixtures	3,510,681	-	-	3,510,681	10	2,972,871	53,781	3,026,652	484,028
Office Equipment	14,723,986	203,900	-	14,927,886	10	11,166,133	407,825	11,573,958	3,353,928
Office By-cycles	15,962	-	-	15,962	20	15,867	19	15,886	76
Books	98,060	-	-	98,060	10	94,020	404	94,424	3,636
Sub Total	216,074,963	23,794,746	-	239,869,709		135,431,706	4,618,518	140,050,224	99,819,485
Injectable (Ampoule) Unit -2									
Factory Building	3,627,409	-	-	3,627,409	10	1,841,404	178,600	2,020,005	1,607,404
Plant and Machinery	9,221,953	-	-	9,221,953	20	7,934,609	257,469	8,192,078	1,029,875
Production Equipment	80,500	-	-	80,500	10	71,046	945	71,992	8,508
Transport and Vehicles	2,235,000	-	-	2,235,000	20	2,218,954	3,209	2,222,163	12,837
Furniture and Fixture	930,903	-	-	930,903	10	839,286	9,162	848,448	82,455
Sub Total	16,095,764	-	-	16,095,764		12,905,300	449,385	13,354,685	2,741,079
Balance on 30 June 2025	232,170,727	23,794,746	-	255,965,473		148,337,004	5,067,903	153,404,907	102,560,566
Balance on 30 June 2024	229,969,447	2,201,280	-	232,170,727		142,493,912	5,843,092	148,337,006	83,833,723

30-06-2025
3,218,507
1,849,396
5,067,903

Note : Depreciation Charged to :
(a) Cost of Goods Sold (Note-25.00)
(b) Administrative Expenses (Note-26.00)

AMBEE PHARMACEUTICALS PLC.
Property, Plant & Equipment
Depreciation Schedule as per Income Tax
For the year ended 30th June 2025

Schedule-B

Particulars	WDV As on 01.07.2024	Addition during year	Adjustment during year	As on 30.06.2025	Rate %	Depreciation	WDV as on 30.06.2025
Existing Units -1							
Land	-	-	-	-	-	-	-
Leasehold Land	-	-	-	-	-	-	-
Factory Building	847,022	-	-	847,022	10	84,702	762,320
Plant and Machinery	844,021	23,590,846	-	24,434,867	20	168,804	24,266,063
Loose Tools	369	-	-	369	10	37	332
Laboratory Equipment	1,406,111	-	-	1,406,111	10	153,387	1,252,724
Electrical Installation	51,341	-	-	51,341	10	5,134	46,206
Laboratory Glass Ware	289	-	-	289	10	29	260
Production Equipment	41,003	-	-	41,003	10	4,100	36,903
Transport and Vehicles	938,639	-	-	938,639	20	187,728	750,911
Motorcycle	5,697,980	-	-	5,697,980	20	1,139,596	4,558,384
Furniture and Fixtures	459,894	-	-	459,894	10	45,989	413,904
Office Equipment	3,504,968	203,900	-	3,708,868	10	350,497	3,358,371
Office By-cycles	27	-	-	27	20	5	22
Books	1,139	-	-	1,139	10	114	1,025
Sub Total	13,792,802	23,794,746	-	37,587,548		2,140,123	35,447,425
Injectable (Ampoule) Unit -2							
Factory Building	22,964	-	-	22,964	10	2,296	20,668
Plant and Machinery	55,923	-	-	55,923	20	11,185	44,738
Production Equipment	1,023	-	-	1,023	10	102	921
Transport and Vehicles	6,435	-	-	6,435	20	1,287	5,148
Furniture and Fixture	74,168	-	-	74,168	10	7,417	66,752
Sub Total	160,513	-	-	160,513		22,287	138,226
Grand Total	13,953,316	23,794,746	-	37,748,062	-	2,162,410	35,585,652